Literature DB >> 7834610

Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines.

Y Kondo1, S M Kuo, S C Watkins, J S Lazo.   

Abstract

Metallothioneins (MT) are major cysteine-rich proteins with poorly characterized functions. We have examined the MT amount, isotype expression, and subcellular distribution in 4 human hormone-independent prostatic carcinoma cell lines. Both PC-3 and DU-145 cells were thiol-rich cells with similar MT and glutathione levels, while HPC36M and PC-3 MA2 were thiol-poor cells with lower MT and glutathione levels. All 4 prostatic cell lines expressed the MTIIA isoform at a basal level; DU-145 cells also constitutively expressed MTIE mRNA. Using antibodies for both total MT and MTIIA, we defined MT to cytoplasmic and nuclear domains in PC-3 cells, to perinuclear and nuclear domains in HPC36M cells, and to prominent nonnucleolar nuclear domains in DU-145 and PC-3 MA2 cells. These results indicate that the subcellular distribution is cell type specific and not reflective of the total MT content or MT isoform. Resistance to cadmium in all 4 cell lines was correlated with total MT levels, while resistance to the anticancer agent cisplatin correlated best with nuclear MT content. We suggest that the subcellular localization of MT is functionally important in cellular protection against the anticancer agent cisplatin in human prostatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7834610

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.

Authors:  Paweł Surowiak; Verena Materna; Adam Maciejczyk; Marek Pudełko; Ewa Markwitz; Marek Spaczyński; Manfred Dietel; Maciej Zabel; Hermann Lage
Journal:  Virchows Arch       Date:  2007-01-19       Impact factor: 4.064

2.  Metallothionein expression in hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Lian-Yue Yang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.

Authors:  S S Chauhan; X J Liang; A W Su; A Pai-Panandiker; D W Shen; J A Hanover; M M Gottesman
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

4.  Zinc binding ligands and cellular zinc trafficking: apo-metallothionein, glutathione, TPEN, proteomic zinc, and Zn-Sp1.

Authors:  Ujala Rana; Rajendra Kothinti; Jeffrey Meeusen; Niloofar M Tabatabai; Susan Krezoski; David H Petering
Journal:  J Inorg Biochem       Date:  2007-11-28       Impact factor: 4.155

5.  Cell line modeling to study biomarker panel in prostate cancer.

Authors:  Bita NickKholgh; Xiaolan Fang; Shira M Winters; Anvi Raina; Komal S Pandya; Kenneth Gyabaah; Nora Fino; K C Balaji
Journal:  Prostate       Date:  2015-11-02       Impact factor: 4.104

6.  Prognostic significance of metallothionein expression in renal cell carcinoma.

Authors:  Dionisios Mitropoulos; Aspasia Kyroudi-Voulgari; Stamatis Theocharis; Efraim Serafetinides; Epaminondas Moraitis; Anastasios Zervas; Christos Kittas
Journal:  World J Surg Oncol       Date:  2005-01-17       Impact factor: 2.754

7.  Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus.

Authors:  Y Hishikawa; T Koji; D K Dhar; S Kinugasa; M Yamaguchi; N Nagasue
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

8.  Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer.

Authors:  R Jin; B H Bay; V T Chow; P H Tan; V C Lin
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

9.  Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

Authors:  Fabian D Mairinger; Jan Schmeller; Sabrina Borchert; Michael Wessolly; Elena Mairinger; Jens Kollmeier; Thomas Hager; Thomas Mairinger; Daniel C Christoph; Robert F H Walter; Wilfried E E Eberhardt; Till Plönes; Jeremias Wohlschlaeger; Bharat Jasani; Kurt Werner Schmid; Agnes Bankfalvi
Journal:  Oncotarget       Date:  2018-04-27

10.  P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.

Authors:  S D Shnyder; A J Hayes; J Pringle; C W Archer
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.